ME01255B - Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik - Google Patents

Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik

Info

Publication number
ME01255B
ME01255B MEP-2011-26A MEP2611A ME01255B ME 01255 B ME01255 B ME 01255B ME P2611 A MEP2611 A ME P2611A ME 01255 B ME01255 B ME 01255B
Authority
ME
Montenegro
Prior art keywords
dosage form
sustained
tablet
release
formulation
Prior art date
Application number
MEP-2011-26A
Other languages
German (de)
English (en)
French (fr)
Inventor
Richard Owen Mannion
William Henry Mckenna
Edward Patrick O'donnell
Haiyong Hugh Huang
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01255(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of ME01255B publication Critical patent/ME01255B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B7/00—Mixing; Kneading
    • B29B7/02—Mixing; Kneading non-continuous, with mechanical mixing or kneading devices, i.e. batch type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B7/00—Mixing; Kneading
    • B29B7/80—Component parts, details or accessories; Auxiliary operations
    • B29B7/88—Adding charges, i.e. additives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/04—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
    • B29C35/045—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/16—Cooling
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C37/00—Component parts, details, accessories or auxiliary operations, not covered by group B29C33/00 or B29C35/00
    • B29C37/0025—Applying surface layers, e.g. coatings, decorative layers, printed layers, to articles during shaping, e.g. in-mould printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/02—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor of articles of definite length, i.e. discrete articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/32—Component parts, details or accessories; Auxiliary operations
    • B29C43/52—Heating or cooling
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
    • B29C71/009—After-treatment of articles without altering their shape; Apparatus therefor using gases without chemical reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
    • B29C35/04—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam
    • B29C35/045—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames
    • B29C2035/046—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould using liquids, gas or steam using gas or flames dried air
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
    • B29C35/16—Cooling
    • B29C2035/1658—Cooling using gas
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2071/00—Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
    • B29K2071/02—Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/25—Solid
    • B29K2105/251—Particles, powder or granules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037—Other properties
    • B29K2995/0088—Molecular weight
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Thermal Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plasma & Fusion (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (32)

1. Čvrst oralni farmaceutski dozni oblik sa produženim oslobađanjem, koji sadrži formulaciju matrice sa produženim oslobađanjem, a formulcija matrice sa produženim oslobađanjem sadrži kompoziciju koja sadrži bar jedan aktivan agens i bar jedan polietilen oksid koji na osnovu reoloških merenja ima približnu molekulsku težinu od najmanje 1,000,000; gde je formulacija matrice sa produženim oslobađanjem očvršćavana na oko 60°C u toku vremenskog perioda od oko 1 minut u obliku tablete ili zrnaca, pri čemu ova tableta ili pojedinačno znce može da se zgnječi bez kidanja, naznačen time, što debljina tablete ili pojedinačnog zrnca posle ovog gnječenja, nije veća od oko 60% debljine te tablete ili pojedinačnog zrnca pre nego što su zgnječeni, pri čemu ova zgnječena ili nezgnječena tableta ili zgnječena ili nezgnječena zrnca imaju brzinu rastvaranja in vitro, merenu u aparatu USP Apparatus 1 (sa korpom), pri 100 o/min, u 900 ml simuliranog želudačnog fluida bez enzima (SŽF), koji sadrži 40% etanola, na 37° C, naznačen time, što procenat oslobođene aktivne supstance tokom 0,5 sati rastvaranja, ne odstupa više od oko 20% od odgovarajuće brzine oslobađanja in vitro, merene u aparatu USP Apparatus 1 (sa korpom), pri 100, o/min, u 900 mL simuliranog želudačnog fluida bez enzima (SŽF), na 37° C, bez etanola, ako se koriste zgnječena ili nezgnječena referentna tableta ili zgnječna ili nezgnječena referentna zrnca, respektivno.
2.    Čvrsti oralni faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 1, gde tableta ili zrnca mogu biti bar zgnječeni bez kidanja, naznačen time, što debiljna tablete ili pojedinačnog zrnca posle gnječenja nije veća od oko 60%, ili nije veća od oko 50%. ili nije veća od oko 40%, ili nije veće od oko 30%. ili nije veća od oko 20%, ili nije veća od oko 16% debljine te tablete ili pojedinačnog zrnca pre nego što su zgnječeni i gde zgnječena i nezgnječena tableta ili pojedinačno zrno imaju brzinu rastvaranja in vitro merenu u aparatu USP Apparatus 1 (sa korpom), pri 100 o/min, u 900 mL simuliranog želudačnog fluida bez enzima (SŽF), koji sadrži 40% etanola, na 37° C, naznačen time, što procenat oslobođene aktivne supstance tokom 0,5 sati rastvaranja, ne odstupa više od oko 20% ili ne više od oko 15% od odgovarajuće brzine oslobađanja in vitro, merene u aparatu USP Apparatus 1 (sa korpom), pri 100 o/min, u 900 mL simuliranog želudačnog fluida bez enzima (SŽF), na 37° C, bez etanola, ako se koriste zgnječena ili nezgnječena referentna tableta ili zrnca, respektivno.
3.    Čvrsti oralni faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 1 ili 2, gde je gustina formulacije matrice sa produženim oslobađanjem jednaka ili manja od oko 1.20 g/cm3, poželjno jednaka ili manja od oko 1.19 g/cm3.
4.    Čvrsti oralni faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 1, gde formulacija matrice sa produženim oslobađanjem posle skladištenja na 25°C i 60% relativne vlažnosti (RH) u toku bar 1 meseca ima brzinu rastvaranja merenu u aparatu USP Apparatus 1 (sa korpom), pri 100 o/min, u 900 mL simuliranog želudačnog fluida bez enzima (SŽF), na 37° C, naznačen time, što procenat oslobođene aktivne supstance tokom 1, 4 i 12 sati rastvaranja, ne odstupa više od oko 15% od odgovarajuće brzine oslobađanja in vitro, referentne formulacije pre skladištenja.
5.    Čvrsti oralni faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 4, gde je formulacija matrice sa produženim oslobađanjem čuvana na 40°C i 75% relativne vlažnosti (RH).
6.    Čvrsti oralni faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 1, gde formulacija matrice sa produženim oslobađanjem posle skladištenja na 25°C i 60% relativne vlažnosti (RH) u toku bar 1 meseca ima količinu bar jednog aktivnog agensa u % (tež.) u odnosu na obeleženu količinu aktivnog agensa za formulaciju matrice sa produženim oslobađanjem koja odstupa ne više od oko 10% od odgovarajuće količine aktivnog agensa u % (tež.) u odnosu na obeleženu količinu aktivnog agensa za formulaciju matrice sa produženim oslobađanjem referentne formulacije pre skladištenja.
7.    Čvrsti oralni faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 6, gde je formualcija sa produženim oslobađanjem bila skladištena na 40°C i 75% relativne vlažnosti (RH).
8.    Čvrsti oralni faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 1, gde dozni oblik ima brzinu rastvaranja merenu u aparatu USP Apparatus 1 (sa korpom), pri 100 o/min, u 900 ml_ simuliranog želudačnog fluida bez enzima (SŽF), na 37° C, koja je između 12.5% i 55% (tež.) oslobođenog aktivnog agensa posle 1 sata, između 25 i 65% (tež.) oslobođenog aktivnog agensa posle 2 sata, između 45 i 85% (tež.) oslobađenog aktivnog agensa posle 4 sata i između 55 i 95% (tež.) oslobađenog aktivnog agensa posle 6 sati.
9.    Čvrsti oralni faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 1, gde je aktivni agens oksikodon hidrohlorid i gde je dozni oblik kada se testira u komparativnom kliničkom ispitivanju bioekvivalentan komercijalnom proizvodu OxyCotin™
10.    Čvrsti oralni faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 1, gde je aktivni agens oksikodon hidrohlorid i gde dozni oblik koji sadrži 10 mg oksikodon hidrohlorida kada je testiran u komparativnom kliničkom ispitivanju je bioekvilaentan sa referentnom tabletom koja sadrži 10 mg oksikodon hidrohlorida u formulaciji matrice koja sadrži: a)    oksikodon hidrohlorid : 10.0 mg/tableti b)    Laktozu (sušenu raspršivanjem): 69.25 mg/ml c)    Povidon: 5.0 mg/tableti d)    Eudragit® RS 30 D (čvrst): 10.0 mg/tableti e)    Triacetin®: 2.0 mg/tableti f)    stearil alkohol: 25.0 mg/tableti g)    talk: 2.5 mg/tableti h)    magnezijum stearat: 1.25 mg/tableti; i gde je referentna tableta pripremljena sledećim stupnjevima: 1.    . Eudragit® RS 30D i Triacetin® se kombinuju prilikom propuštanja kroz sito od 60 mesa, pa 5 min mešaju uz nisko smicanje, ili dok se ne dobije uniformna disperzija 2.    . Oksikodon HCI, laktoza i povidon se stave u fluidizacionu kolonu koja je granulator/sušnica (FBD), pa se ova suspenzija rasprši u prah u fluidizacionoj koloni 3.    . Posle raspršivanja, granulat se propušta kroz sito #12, ukoliko je potrebno da se smanje grudvice 4.    . Ovaj suvi granulat se prebaci u mikser 5.    . U međuvremenu, otopi se potrebna količina stearil alkohola, na temperaturi od približno 70°C 6.    . Istopljeni stearil alkohol se uz mešanje doda u granulat 7. . Ovako voskiran granulat se prebaci u fluidizacionu kolonu, koja je istovremeno granulator/sušnica, ili na tacne, pa se ostavi da se ohladi na sobnu ili nižu temperaturu 8.    Ovako ohlađeni granulat se propusti kroz sito #12 9.    Ovaj voskirani granulat se prebaci u mikser/blender, i približno 3 min podmazuje sa potrebnom količinom talka i magnezijum-stearata 10.    Ovaj granulat se komprimuje u tablete od 125 mg, u pogodnoj mašini za tabletiranje.
11. Dozni oblik sa produženim oslobađanjem prema bilo kom zahtevu 1 do 10, gde kompozicija sadrži bar oko 80% (tež.) polietilen oksida.
12.    Dozni oblik sa produženim oslobađanjem prema zahtevu 11, gde kompozicija sadrži bar oko 80% (tež.) polietilen oksida, koji na osnovu reoloških merenja ima približnu molekulsku težinu od najmanje 1,000,000.
13.    Faramceutski dozni oblik sa produženim oslobađanjem prema bilo kom od zahteva 1 do 8, gde je aktivni agens opioidini analgetik.
14.    Faramceutski dozni oblik sa produženim oslobađanjem prema zahtevu 13, što se opijatni analgetik bira iz grupe koju čine alfentanil, alilprodin, alfaorodin, anileridin, benzilmorfin, bezitramid, buprenorfin, butorfanol, klonitazen, kodein, dezomorfin, dekstromoramid, dezocin, diampromid, diamorfon, dihidrokodein, dihidromorfin, dimenoksadol, dimefeptanol, dimetiltiambuten, dioksafetil butirat, dipipanon, eptazocin, etoheptazin, etilmetiltiambuten, etilmorfin, etonitazen, etorfin, dihidroetorfin, fentanil i derivati, hidrokodon, hidrmorfon, hidroksipethidine, izometadon, ketobemidon, levorfanol, levofenancilmorfan, lofentanil, meperidin, meptazinol, metazocin, metadon, metopon, morfin, mirofin, narcein, nikomorfin, norlevorfanol, normetadon, nalorfin, nalbufen, normorfin, norpipanon, opium, oksikodon, oksimorfon, papaveretum, pentazocin, phenadoksone, fenomorfan, fenezocin, fenoperidin, piminodin, piritramid, propheptazin, promedol, properidin, propoksifen, sufentanil, tilidin, tramadol, njihove farmaceutski prihvatljive soli, hidrati i solvati, smeše navedenih.
15.    Dozni oblik sa produženim oslobađanjem prema zahtevu 13, gde je opioidni analgetik izabran iz grupe koju čine kodein, morfin, oksikodon, hidrokodon, hidromoron ili oksimorfon ili njihove faramaceutski prihvatljive soli, hidrati i solvati, smeše bilo koga od pomenutih.
16.    Dozni oblik sa produženim oslobađanjem prema zahtevu 9 ili 14, gde je opioidni analgetik oksikodon hidrohlorid i dozni oblik sadrži od oko 5 mg do oko 500 mg oksikodon hidrohlorida.
17.    Dozni oblik sa produženim oslobađanjem prema zahtevu 16, gde dozni oblik obuhvata 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg ili 80 mg, 90 mg, 120 mg ili 160 mg oksikodon hidrohlorida.
18.    Dozni oblik sa produženim oslobađanjem prema bilo kom od zahteva 9, 10 i 13, gde je opioidni analgetik oksikodon hidrohlorid koji ima nivo 14-hidroksikodeinona manji od oko 25 ppm, poželjno manji od oko 15 ppm, manji od oko 10 ppm ili manji od oko 5 ppm.
19.    Dozni oblik sa produženim oslobađanjem prema zahtevu 13, gde je opioidini analgetik oksimorfon hidrohlorid i dozni oblik sadrži od oko 1 mg do oko 500 mg oksimorfon hidrohlorida.
20.    Dozni oblik sa produženim oslobađanjem prema zahtevu 19, gde dozni oblik sadrži 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg ili 80 mg, 90 mg, 120 mg illi 160 mg oksimorfon hidrohlorida.
21.    Dozni oblik sa produženim oslobađanjem prema zahtevu 13, gde je opioidni analgetik hidromorfon hidrohlorid i dozni oblik sadrži od oko 1 mg do oko 100 mg hidromorfon hidrohlorida.
22.    Dozni oblik sa produženim oslobađanjem prema zahtevu 21, gde dozni oblik sadrži 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg ili 64 mg hidromorfon hidrohlorida.
23.    Dozni oblik sa produženim oslobađanjem prema bilo kom od zahteva 1 do 22, koji je u obliku tablete obrazovane direktnim komprimovanjem i očvršćavanjem bar podvrgavanjem pomenute tablete na temperaturu od oko 60°C ili na bar oko 62°C u toku vremenskog perioda od oko 1 minut, poželjno od oko 5 minuta ili bar oko 15 minuta.
24.    Dozni oblik sa produženim oslobađanjem prema bilo kom od zahteva 1 do 23, koji je u obliku tablete i koji je prevučen sa slojem polietilen oksida u prahu da bi se obrazovala tableta koja ima jezgro i sloj polietilen oksida koji okružuje jezgro tablete.
25.    Dozni oblik sa produženim oslobađanjem prema bilo kom od zahteva 1 do 23, koji je u obliku složene dvoslojne ili višeslojene tablete, gde jedan od slojeva sadrži formulaciju sa produženim oslobađanjem, a jedan od ostalih slojeva sadrži formulaciju za trenutno oslobađanje.
26.    Dozni oblik sa produženim oslobađanjem prema zahtevu 25, gde formulacija sa produženim oslobađanjem i formulacija za trenutno oslobađanje sadrže iste ili razičite aktivne agense.
27.    Dozni oblik sa produženim oslobađanjem prema zahtevu 25, gde formulacija za produženo oslobađanje sadrži opioidni analgetik i formulaciju za trenutno oslobađanje koja sadrži neopioidni analgetik.
28.    Upotreba doze prema bilo kom od zahteva 1 do 27 u proizvodnji leka za lečenje bola, gde dozni oblik sadrži opioidni analgetik.
29.    Upotreba polietilen oksida visoke molekulske težine koja zasnovano na osnovu reoloških merenja ima molekulsku težinu bar 1,000,000, kao materijala za obrazovanje matrice u proizvodnji čvrstog oralnog doznog oblika sa produženim oslobađanjem koji sadrži aktivni agens izabran od opioida koji čine čvrsti oralni dozni oblik sa produženim oslobađanjem otpornim na ekstrakciju alkoholom.
30.    Farmaceutska tableta prema prethodnim zahtevima, koja ima silu stvaranja naprsline od bar 11 ON, poželjno 120N, poželjnije 130N i čak još poželjnije 140N kada je podvrgnuta testu utiskivanja .
31.    Farmaceutska tableta prema prethodnim zahtevima, koja ima rastojanje duž dubine prodiranja naprsline od bar 1.0 mm, poželjno 1.2 mm, poželjnije 1.4 mm i čak poželjnije 1.6 mm kada je podvrgnuta testu utiskivanja.
32.    Farmaceutska tableta prema prethodnim zahtevima, što je otporna pri radu na bar 0.06 J bez pucanja.
MEP-2011-26A 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik ME01255B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84024406P 2006-08-25 2006-08-25
EP09156832A EP2070538B1 (en) 2006-08-25 2007-08-24 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic

Publications (1)

Publication Number Publication Date
ME01255B true ME01255B (me) 2013-06-20

Family

ID=38754532

Family Applications (7)

Application Number Title Priority Date Filing Date
MEP-2011-79A ME01187B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik
MEP-2013-58A ME01550B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici
MEP-2011-27A ME01339B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik
MEP-2012-105A ME01482B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik
MEP-2013-67A ME01580B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici
MEP-2009-348A ME01064B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik
MEP-2011-26A ME01255B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik

Family Applications Before (6)

Application Number Title Priority Date Filing Date
MEP-2011-79A ME01187B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik
MEP-2013-58A ME01550B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici
MEP-2011-27A ME01339B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik
MEP-2012-105A ME01482B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik
MEP-2013-67A ME01580B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici
MEP-2009-348A ME01064B (me) 2006-08-25 2007-08-24 Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik

Country Status (41)

Country Link
US (69) US8894987B2 (me)
EP (11) EP2082742B1 (me)
JP (8) JP5069300B2 (me)
KR (8) KR101649838B1 (me)
CN (9) CN102657630B (me)
AP (1) AP2009004770A0 (me)
AR (4) AR062511A1 (me)
AT (5) ATE499101T1 (me)
AU (1) AU2007287341B2 (me)
BR (2) BR122016004010B8 (me)
CA (2) CA2661573C (me)
CL (3) CL2007002485A1 (me)
CO (1) CO6160317A2 (me)
CR (2) CR10691A (me)
CY (7) CY1110573T1 (me)
DE (5) DE602007012747D1 (me)
DK (11) DK2399579T3 (me)
DO (2) DOP2009000026A (me)
EA (3) EA031873B1 (me)
ES (11) ES2361721T3 (me)
GT (2) GT200900023A (me)
HR (11) HRP20090688T1 (me)
IL (10) IL197214A (me)
IN (1) IN2015DN01813A (me)
JO (2) JO2858B1 (me)
MA (1) MA30766B1 (me)
ME (7) ME01187B (me)
MX (2) MX2009002023A (me)
MY (3) MY153092A (me)
NZ (3) NZ608651A (me)
PE (5) PE20191048A1 (me)
PL (11) PL2311459T3 (me)
PT (11) PT2070538E (me)
RS (11) RS52813B (me)
SA (1) SA07280459B1 (me)
SI (11) SI2292229T1 (me)
TN (1) TN2009000059A1 (me)
TW (1) TWI341213B (me)
UA (2) UA104745C2 (me)
WO (1) WO2008023261A1 (me)
ZA (1) ZA200900755B (me)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2959893A1 (en) 2002-12-13 2015-12-30 DURECT Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2581287C (en) 2004-09-17 2015-08-25 Durect Corporation Sustained local anesthetic composition containing bupivacaine and saib
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2117521B1 (en) 2006-11-03 2012-06-27 Durect Corporation Transdermal delivery systems comprising bupivacaine
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
CN105534936B (zh) 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
AU2009207796B2 (en) * 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (en) * 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
MX342643B (es) * 2008-09-18 2016-10-07 Purdue Pharma Lp Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010066034A1 (en) 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
CA2751627A1 (en) 2009-02-06 2010-08-12 Egalet Ltd. Pharmaceutical compositions resistant to abuse
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
CA2760689A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
US20100278915A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
EP2473195A4 (en) * 2009-08-31 2013-01-16 Depomed Inc PHARMACEUTICAL MAGNETIC RELEASE COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHES
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011095314A2 (en) 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
SE1251371A1 (sv) 2010-05-10 2012-12-27 Euro Celtique Sa Farmaceutiska kompositioner innefattande hydromorfon och naloxon
EP2568968B1 (en) 2010-05-10 2017-07-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
KR101831616B1 (ko) 2010-06-15 2018-04-04 그뤼넨탈 게엠베하 통증 치료용 약제학적 병용물
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
US9233076B2 (en) 2010-12-13 2016-01-12 Purdue Pharma L.P. Controlled release dosage forms
CN104856966A (zh) * 2010-12-22 2015-08-26 普渡制药公司 包覆的抗篡改控制释放剂型
AU2011346757B2 (en) 2010-12-22 2015-08-20 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
WO2012131463A2 (en) * 2011-03-25 2012-10-04 Purdue Pharma L.P. Controlled release pharmaceutical dosage forms
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
AT511581A1 (de) 2011-05-26 2012-12-15 G L Pharma Gmbh Orale retardierende formulierung
PL2736495T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
WO2013038268A1 (en) * 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
US20140341984A1 (en) * 2011-09-16 2014-11-20 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2013057570A2 (en) * 2011-10-18 2013-04-25 Purdue Pharma L.P. Acrylic polymer formulations
PE20141671A1 (es) 2011-11-17 2014-11-22 Gruenenthal Chemie Forma de dosis farmaceutica oral a prueba de manipulacion que comprende un agente antagonista y/o repelente opioide, oxido de polialquileno y un polimero anionico
US20150224097A1 (en) * 2011-11-22 2015-08-13 Watson Pharmaceuticals, Inc. Immediate Release Abuse Deterrent Tablet
US20150265536A1 (en) * 2011-12-09 2015-09-24 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN104684548A (zh) * 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
RU2018141241A (ru) 2012-11-30 2019-01-24 Экьюра Фармасьютикалз, Инк. Саморегулируемое высвобождение фармацевтического ингредиента
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US20140275149A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
ES2681952T3 (es) 2013-03-15 2018-09-17 SpecGx LLC Forma farmacéutica sólida disuasoria del abuso de liberación inmediata con puntaje funcional
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015120201A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015145459A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
HUE065006T2 (hu) 2014-07-03 2024-04-28 SpecGx LLC Nem-cellulóz poliszacharidokat tartalmazó, visszaélés-gátló, azonnali felszabadulású készítmények
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
JP5888387B1 (ja) * 2014-10-22 2016-03-22 ミツミ電機株式会社 電池保護回路及び電池保護装置、並びに電池パック
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
CA2983648A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix
CA2983640A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from different particles
EP3285747A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CA3000418A1 (en) * 2015-09-30 2017-04-06 Kashiv Pharma Llc Overdose protection and abuse deterrent immediate release drug formulation
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
CA3003950C (en) * 2015-10-23 2020-05-12 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
US11065246B2 (en) 2016-02-08 2021-07-20 SpecGx LLC Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
US20170296476A1 (en) 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
KR102413459B1 (ko) 2016-07-06 2022-06-24 듀렉트 코퍼레이션 약물 조성물, 장벽 층 및 약물 층을 갖는 경구 투여 형태
US20180028670A1 (en) 2016-08-01 2018-02-01 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polysaccharide
EP3496702A1 (en) 2016-08-12 2019-06-19 Grünenthal GmbH Tamper resistant formulation of ephedrine and its derivatives
DE202016105585U1 (de) * 2016-10-06 2017-01-23 L.B. Bohle Maschinen + Verfahren Gmbh Anlage zur Herstellung pharmazeutischer Tabletten
USD857156S1 (en) * 2016-11-02 2019-08-20 Innovative Water Care, Llc Chemical tablet for aquatic systems
US11541125B2 (en) 2016-12-19 2023-01-03 The Regents Of The University Of California Noncrushable pill formulations
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019003062A1 (en) * 2017-06-29 2019-01-03 Zenvision Pharma Llp INVIOLABLE GALENIC FORM COMPRISING A PHARMACEUTICALLY ACTIVE AGENT
KR102642847B1 (ko) * 2017-07-10 2024-03-04 젤 캡 테크놀로지스 엘엘씨 이중 방출 투여형 캡슐 및 이를 제조하기 위한 방법, 장치 및 시스템
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AU2018349031A1 (en) 2017-10-13 2020-03-26 Grünenthal GmbH Modified release abuse deterrent dosage forms
CA3075292A1 (en) * 2017-10-20 2019-04-25 Purdue Pharma L.P. Pharmaceutical dosage forms
CA3085348A1 (en) * 2017-12-20 2019-06-27 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
TW202002957A (zh) 2018-02-09 2020-01-16 德商歌林達有限公司 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物
EP3755785A1 (en) 2018-02-22 2020-12-30 The Procter & Gamble Company Methods for making unit dose articles
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
BR112021004213A2 (pt) * 2018-09-06 2021-05-25 Fachhochschule Nordwestschweiz forma de dosagem de formulação farmacêutica e método para preparar uma forma de dosagem de formulação farmacêutica
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070547A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
EP3860579A1 (en) 2018-10-05 2021-08-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2020079699A1 (en) * 2018-10-16 2020-04-23 M.O Advanced Technologies (Moat) Ltd Apparatus and method for prediction of tablet defects propensity
CN111251521B (zh) * 2018-12-03 2022-07-22 沈欣 液态珠丸的制造方法
EP3698776A1 (en) 2019-02-19 2020-08-26 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CN113993523A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗抑郁症和其他各种病症
US20220408745A1 (en) * 2019-09-13 2022-12-29 Meiji Co., Ltd. Solid food and solid milk having hole penetrating first face and second face
CN110946086B (zh) * 2019-12-04 2023-05-12 北京猫猫狗狗科技有限公司 一种下料装置以及下料控制方法
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
US12268658B2 (en) 2019-12-30 2025-04-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
USD943706S1 (en) * 2020-06-10 2022-02-15 Emily Florence Johns Shower steamer
EP4277702A1 (en) 2021-01-12 2023-11-22 Durect Corporation Sustained release drug delivery systems and related methods
CN114659554B (zh) * 2022-03-01 2023-04-25 安徽农业大学 一种生物质颗粒机故障诊断方法
WO2025057111A1 (en) 2023-09-12 2025-03-20 Clexio Biosciences Ltd. Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive disorder

Family Cites Families (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1468805A (en) 1923-09-25 Htabtin ereund
US1479293A (en) 1924-01-01 Hiabtor fbettlid
US1485673A (en) 1924-03-04 Ministrator
US636438A (en) 1899-02-08 1899-11-07 Charles H Lovejoy Molder's chaplet.
US2654756A (en) 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3097144A (en) 1960-10-14 1963-07-09 Upjohn Co Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US3806603A (en) 1969-10-13 1974-04-23 W Gaunt Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm
US3885027A (en) 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3966747A (en) 1972-10-26 1976-06-29 Bristol-Myers Company 9-Hydroxy-6,7-benzomorphans
US3888027A (en) 1973-07-30 1975-06-10 Kennametal Inc Arrangement for enhancing blade life
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3941865A (en) 1973-12-10 1976-03-02 Union Carbide Corporation Extrusion of ethylene oxide resins
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
GB1598458A (en) 1977-04-01 1981-09-23 Hoechst Uk Ltd Tableting of microcapsules
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4211681A (en) 1978-08-16 1980-07-08 Union Carbide Corporation Poly(ethylene oxide) compositions
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3002664C2 (de) 1980-01-25 1989-05-18 Titmus Eurocon Kontaktlinsen Gmbh & Co Kg, 8750 Aschaffenburg Weiche Kontaktlinse
IL70071A (en) 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4501828A (en) 1983-01-20 1985-02-26 General Technology Applications,Inc. Dissolving water soluble polymers
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
FR2557459B1 (fr) 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
AU592065B2 (en) 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4616644A (en) 1985-06-14 1986-10-14 Johnson & Johnson Products, Inc. Hemostatic adhesive bandage
WO1987000045A1 (en) 1985-06-24 1987-01-15 Ici Australia Limited Ingestible capsules
US4619988A (en) 1985-06-26 1986-10-28 Allied Corporation High strength and high tensile modulus fibers or poly(ethylene oxide)
DE3665262D1 (en) 1985-06-28 1989-10-05 Carrington Lab Inc Processes for preparation of aloe products, products produced thereby and compositions thereof
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
EP0226061B1 (en) 1985-12-17 1994-02-16 United States Surgical Corporation High molecular weight bioresorbable polymers and implantation devices thereof
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
ES2032802T5 (es) 1986-11-10 2004-01-16 Biopure Corporation Sucedaneo de sangre semisintetico extrapuro.
DE3643789A1 (de) 1986-12-20 1988-06-30 Bayer Ag Thermoplastisch verarbeitbare, im wesentlichen lineare poly-(alpha)-aryl-olefin/polyurethan-blockcopolymere, verfahren zu deren herstellung und deren verwendung
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US4960814A (en) 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5139790A (en) 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5004601A (en) 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5051222A (en) 1989-09-01 1991-09-24 Air Products And Chemicals, Inc. Method for making extrudable polyvinyl alcohol compositions
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5200197A (en) 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
FR2664851B1 (fr) 1990-07-20 1992-10-16 Oreal Procede de compactage d'un melange pulverulent permettant d'obtenir un produit compact absorbant ou partiellement delitable et produit obtenu par ce procede.
SE9003904D0 (sv) 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
AU2670292A (en) 1991-10-04 1993-05-03 Olin Corporation Fungicide tablet
WO1993010163A2 (en) 1991-11-12 1993-05-27 Nepera, Inc. Adhesive hydrogels having extended use lives and process for the preparation of same
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
DE69212497T2 (de) 1991-12-05 1996-12-12 Mallinckrodt Veterinary, Inc., Mundelein, Ill. Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
CA2124821C (en) 1991-12-18 2003-10-07 Isaac Ghebre-Sellassie Novel solid pharmaceutical dispersions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
ES2096103T3 (es) 1992-01-13 1997-03-01 Pfizer Preparacion de comprimidos de resistencia incrementada.
US5393528A (en) 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
DK0661045T3 (da) 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
AU679937B2 (en) 1992-11-18 1997-07-17 Johnson & Johnson Consumer Products, Inc. Extrudable compositions for topical or transdermal drug delivery
FR2701152B1 (fr) 1993-02-03 1995-03-10 Digipress Sa Procédé de fabrication d'un disque maître pour la réalisation d'une matrice de pressage notamment de disques optiques, matrice de pressage obtenue par ce procédé et disque optique obtenu à partir de cette matrice de pressage.
DE4309528C2 (de) 1993-03-24 1998-05-20 Doxa Gmbh Folie oder Folienschlauch aus Casein, Verfahren zu deren Herstellung und deren Verwendung
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
EP2036558A3 (en) 1993-10-07 2010-04-28 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
US5776146A (en) 1993-10-20 1998-07-07 Applied Medical Resources Laparoscopic surgical clamp
DK0654263T3 (da) 1993-11-23 2002-04-29 Euro Celtique Sa Fremgangsmåde til fremstilling af et præparat med langvarig frigivelse
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
ES2199981T3 (es) 1994-02-16 2004-03-01 Abbott Laboratories Modo de preparacion de formulaciones farmaceuticas de particulas finas.
AU1702395A (en) 1994-02-17 1995-09-04 Pankaj Modi Drugs, vaccines and hormones in polylactide coated microspheres
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
PT758244E (pt) 1994-05-06 2002-04-29 Pfizer Formas de dosagem libertacao controlada de azitromicina
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5914131A (en) 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
CA2130410C (en) 1994-08-18 2001-12-04 Albert John Kerklaan Retractable expandable jack
SE9402807L (sv) 1994-08-23 1995-08-28 Ecept Ab Gravstensfäste
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5516808A (en) 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4446470A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
WO1996032097A1 (fr) 1995-04-14 1996-10-17 Pharma Pass Compositions solides contenant du polyethyleneoxyde et un principe actif non amorphe
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5634702A (en) 1995-09-27 1997-06-03 Fistonich; Juraj Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
DE19547766A1 (de) 1995-12-20 1997-06-26 Gruenenthal Gmbh 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe
US5783212A (en) 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
CA2248738A1 (en) 1996-03-11 1997-09-18 Kurt Rasmussen Use of olanzapine for treating substance abuse
DK0914097T3 (da) 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US20020114838A1 (en) 1996-04-05 2002-08-22 Ayer Atul D. Uniform drug delivery therapy
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
DE69723248T2 (de) 1996-04-10 2004-05-27 Warner-Lambert Co. Llc Vergällungsstoffe für sympathomimetische aminsalze
US5886164A (en) 1996-04-15 1999-03-23 Zeneca Limited DNA encoding enzymes related to ethylene biosynthesis and ripening from banana
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
AU3404997A (en) 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
US5955096A (en) 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
AU3508097A (en) 1996-06-26 1998-01-14 Board Of Regents, The University Of Texas System Hot-melt extrudable pharmaceutical formulation
US5730564A (en) 1996-07-24 1998-03-24 Illinois Tool Works Inc. Cargo load supporting air bag having inflation indicating means, and method of determining proper inflation for spaced loads
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
DE19630236A1 (de) 1996-07-26 1998-01-29 Wolff Walsrode Ag Biaxial gereckte, biologisch abbaubare und kompostierbare Wursthülle
BE1010353A5 (fr) 1996-08-14 1998-06-02 Boss Pharmaceuticals Ag Procede pour la fabrication de produits pharmaceutiques, dispositif pour un tel procede et produits pharmaceutiques ainsi obtenus.
ATE278737T1 (de) 1996-11-05 2004-10-15 Novamont Spa Biologiscgh abbaure polymerzusammensetzungen, die stärke und ein thermoplastisches polymer enthalten
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
FR2761605B1 (fr) 1997-04-07 2001-02-23 Prographarm Lab Forme pharmaceutique multiparticulaire, ses particules constitutives, procede et installation pour leur fabrication
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
IL121038A0 (en) 1997-06-09 1997-11-20 Technion Res & Dev Foundation A pharmaceutical composition for lowering glucose level in blood
DE19724181A1 (de) 1997-06-09 1998-12-10 Bayer Ag Multiple-unit-retard-Zubereitungen und Verfahren zu ihrer Herstellung
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
ATE322892T1 (de) 1997-07-02 2006-04-15 Euro Celtique Sa Stabilisierte tramadol formulierungen mit verzögerter freisetzung
DE69806399T2 (de) 1997-09-26 2003-02-20 Magna Interior Systems Inc., Aurora Befestigungsvorrichtung zum verbinden von zwei innenpaneelen
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
ATE214595T1 (de) 1997-11-28 2002-04-15 Knoll Ag Verfahren zur herstellung von lösungsmittelfreien nicht-kristallinen biologisch aktiven substanzen
DE19753534A1 (de) 1997-12-03 1999-06-10 Bayer Ag Schnell kristallisierende, biologisch abbaubare Polyesteramide
GB9726365D0 (en) 1997-12-13 1998-02-11 Ciba Sc Holding Ag Compounds
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
BR9813728A (pt) 1997-12-22 2000-10-10 Schering Corp Composição de dispersão molecular com elevada biodisponibilidade
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
DE19800698A1 (de) 1998-01-10 1999-07-15 Bayer Ag Biologisch abbaubare Polyesteramide mit blockartig aufgebauten Polyester- und Polyamid-Segmenten
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6235825B1 (en) 1998-03-05 2001-05-22 Mitsui Chemicals, Inc. Polylactic acid resin composition and film therefrom
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6852337B2 (en) 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
DE19822979A1 (de) 1998-05-25 1999-12-02 Kalle Nalo Gmbh & Co Kg Folie mit Stärke oder Stärkederivaten und Polyesterurethanen sowie Verfahren zu ihrer Herstellung
EP0974343B1 (en) 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
DE19838636A1 (de) 1998-08-26 2000-03-02 Basf Ag Carotinoid-Formulierungen, enthaltend ein Gemisch aus beta-Carotin, Lycopin und Lutein
DE19855440A1 (de) 1998-12-01 2000-06-08 Basf Ag Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion
IE981008A1 (en) 1998-12-02 2000-06-14 Fuisz Internat Ltd Microparticles Containing Water Insoluble Active Agents
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
US6451604B1 (en) 1999-06-04 2002-09-17 Genesis Research & Development Corporation Limited Compositions affecting programmed cell death and their use in the modification of forestry plant development
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6403703B1 (en) 1999-08-27 2002-06-11 Rohm And Haas Company Polymeric compositions from acrylic and unsaturated carboxyl monomers
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
NZ517559A (en) 1999-08-31 2004-08-27 Gruenenthal Chemie Sustained release pharmaceutical composition containing tramadol saccharinate
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6491683B1 (en) 1999-09-07 2002-12-10 Alza Corporation Osmotic dosage form composed of an extruded polymer tube form
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
DE19960494A1 (de) 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
US6638881B2 (en) 1999-12-23 2003-10-28 Combe Incorporated Dental adhesive device and method of producing same
US6630086B1 (en) 1999-12-30 2003-10-07 Ethicon, Inc. Gas assist molding of one-piece catheters
ECSP003314A (es) 2000-01-11 2000-03-22 Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide y un - agonista
US6680070B1 (en) 2000-01-18 2004-01-20 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
US6277409B1 (en) 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
DE10025947A1 (de) 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination enthaltend Montirelin und eine Verbindung mit opioider Wirksamkeit
DE10025948A1 (de) 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
AU2001258825A1 (en) 2000-05-29 2001-12-11 Shionogi And Co., Ltd. Method for labeling with tritium
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
DE10036400A1 (de) 2000-07-26 2002-06-06 Mitsubishi Polyester Film Gmbh Weiße, biaxial orientierte Polyesterfolie
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2002026928A1 (en) 2000-09-28 2002-04-04 The Dow Chemical Company Polymer composite structures useful for controlled release systems
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CA2778114A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
EP1392250A2 (en) 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
WO2003002100A1 (en) 2001-06-26 2003-01-09 Farrell John J Tamper-proof narcotic delivery system
DE60223254T2 (de) 2001-07-06 2008-08-14 Penwest Pharmaceuticals Co. Verzögert freisetzende formulierungen von oxymorphon
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
AU2002321879A1 (en) 2001-08-06 2003-03-03 Thomas Gruber Pharmaceutical formulation containing dye
BR0212019A (pt) 2001-08-06 2005-08-09 Euro Celtique Sa Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
DE20220917U1 (de) 2001-08-06 2004-08-19 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
US20030069318A1 (en) 2001-08-21 2003-04-10 Wenbin Dang Salts of analgesic substances in oil, and methods of making and using the same
US6691698B2 (en) 2001-09-14 2004-02-17 Fmc Technologies Inc. Cooking oven having curved heat exchanger
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
AU2002342755A1 (en) 2001-09-26 2003-04-14 Klaus-Jurgen Steffens Method and device for producing granulates that comprise at least one pharmaceutical active substance
US6982094B2 (en) 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
BR0212951A (pt) 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas
US20030229158A1 (en) 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
FR2833838B1 (fr) 2001-12-21 2005-09-16 Ellipse Pharmaceuticals Procede de fabrication d'un comprime incluant un analgesique de type morphinique et comprime obtenu
US6938129B2 (en) 2001-12-31 2005-08-30 Intel Corporation Distributed memory module cache
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
ES2377729T3 (es) 2002-02-21 2012-03-30 Valeant International (Barbados) Srl Formulaciones de liberación modificada de al menos una forma de tramadol
GB0204772D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
US20030181882A1 (en) 2002-03-22 2003-09-25 Yasuo Toyoshima Absorbent article
DE10217232B4 (de) 2002-04-18 2004-08-19 Ticona Gmbh Verfahren zur Herstellung gefüllter Granulate aus Polyethylenen hohen bzw. ultrahohen Molekulargewichts
NZ536252A (en) 2002-04-29 2007-06-29 Alza Corp Methods and dosage forms for controlled delivery of oxycodone
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
EP1515674A4 (en) 2002-05-13 2008-04-09 Endo Pharmaceuticals Inc AGAINST MISUSE PROTECTED SOLID OPIOID DOSAGE FORM
CN1653050B (zh) * 2002-05-17 2013-04-24 詹肯生物科学公司 阿片和阿片样化合物及其用途
BR0304960A (pt) 2002-05-31 2005-01-04 Alza Corp Formas de dosagem e composições para liberação osmótica de dosagens variáveis de oxicodona
DE10250083A1 (de) 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
WO2004004693A1 (en) 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US6853758B2 (en) 2002-07-12 2005-02-08 Optimer Photonics, Inc. Scheme for controlling polarization in waveguides
US20040011806A1 (en) 2002-07-17 2004-01-22 Luciano Packaging Technologies, Inc. Tablet filler device with star wheel
WO2004010982A1 (en) 2002-07-25 2004-02-05 Pharmacia Corporation Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
WO2004016618A1 (en) 2002-08-15 2004-02-26 Noramco, Inc. Oxycodone-hydrochloride polymorhs
BR0314251A (pt) 2002-09-20 2005-07-26 Fmc Corp Composição, e, método para a plicação de uma composição cosmética
JP5189242B2 (ja) 2002-09-23 2013-04-24 アルケルメス ファーマ アイルランド リミテッド 乱用抵抗性の医薬組成物
CA2500311A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Modified release dosage forms
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250088A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US7093059B2 (en) 2002-12-31 2006-08-15 Intel Corporation Read-write switching method for a memory controller
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
MXPA05011071A (es) 2003-04-21 2005-12-12 Euro Celtique Sa Forma de dosificacion resistente a la alteracion que comprende particulas co-extrusionadas de agente adverso y proceso de fabricacion de las misma.
MXPA05011703A (es) 2003-04-30 2006-01-23 Purdue Pharma Lp Forma de dosis transdermica resistente a los retardadores que comprende un componente de agente activo y un componente de agente adverso en el sitio distal de la capa del agente activo.
WO2004100883A2 (en) 2003-05-06 2004-11-25 Bpsi Holdings, Inc. Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutual dosage forms and methods of preparing the same
US20040241234A1 (en) 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
US6864370B1 (en) 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050031655A1 (en) 2003-08-04 2005-02-10 Schering Plough Healthcare Products, Inc. Emulsion composition
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
FR2858749B1 (fr) 2003-08-14 2006-03-17 Marcel Legris Ruche permettant a l'abeille et a l'apiculteur de lutter radicalement contre le varroa jacobsoni tout en ameliorant la production de miel
KR20060115860A (ko) * 2003-09-26 2006-11-10 알자 코포레이션 활성 제제의 서방성 전달을 위한 ｏｒｏｓ 푸시-스틱
CA2874604A1 (en) 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
WO2005041968A2 (en) 2003-10-29 2005-05-12 Alza Corporation Once-a-day, oral, controlled-release, oxycodone dosage forms
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
ATE487799T1 (de) 2003-12-23 2010-11-15 Autogenomics Inc Multiplexanalyse von nukleinsäuren zur bestimmung von genotypen des humanen papillomavirus
WO2005070760A1 (en) 2004-01-23 2005-08-04 Antoine Sakellarides Shock absorbing system for rowing boat oarlock
EP1750717B1 (en) 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403760D0 (en) 2004-02-20 2004-03-24 Clements Paul Digging implement
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
JP5064209B2 (ja) * 2004-04-22 2012-10-31 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用防止固体剤形を製造する方法
JP2006002884A (ja) * 2004-06-18 2006-01-05 Mitsubishi Plastics Ind Ltd 連結具
JP2006002886A (ja) * 2004-06-18 2006-01-05 Noriatsu Kojima 排水管
WO2006002286A1 (en) * 2004-06-22 2006-01-05 Magna International Inc. Sealing molding for a motor vehicle
PL1765303T5 (pl) 2004-07-01 2023-05-22 Grünenthal GmbH Tabletka doustna zabezpieczona przed nadużywaniem
EP1765298B1 (de) 2004-07-01 2012-10-24 Gruenenthal Gmbh Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1786403B1 (de) 2004-07-01 2013-07-24 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
EP3228308A1 (en) 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20080274183A1 (en) 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
AU2006269225B2 (en) 2005-07-07 2011-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US7778314B2 (en) 2006-05-04 2010-08-17 Texas Instruments Incorporated Apparatus for and method of far-end crosstalk (FEXT) detection and estimation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2671518C (en) 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
MX2009007254A (es) 2007-01-12 2009-08-12 Wyeth Corp Composiciones de tableta en tableta.
CA2930487A1 (en) 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
CA2720108C (en) 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
EP2260677A2 (en) 2008-03-11 2010-12-15 Robe Lighting Inc. Led array luminaires
US8671872B2 (en) 2009-02-16 2014-03-18 Thomas Engineering Inc. Production coater with exchangeable drums
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
US9492492B2 (en) * 2010-12-17 2016-11-15 Johnson & Johnson Consumer Inc. Compositions comprising Lilium martagon extracts and uses thereof
AU2011346757B2 (en) * 2010-12-22 2015-08-20 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9846413B2 (en) * 2011-09-08 2017-12-19 Fire Avert, Llc. Safety shut-off device and method of use
US10764498B2 (en) * 2017-03-22 2020-09-01 Canon Kabushiki Kaisha Image processing apparatus, method of controlling the same, and storage medium
US10764499B2 (en) * 2017-06-16 2020-09-01 Microsoft Technology Licensing, Llc Motion blur detection
CA3073570C (en) * 2017-08-31 2025-07-08 Purdue Pharma L.P. Delayed-release oral opioid formulations comprising an anionic surfactant and polyethylene oxide
CA3075292A1 (en) * 2017-10-20 2019-04-25 Purdue Pharma L.P. Pharmaceutical dosage forms

Also Published As

Publication number Publication date
JP5069300B2 (ja) 2012-11-07
CN102657630B (zh) 2014-10-01
RS52798B (sr) 2013-10-31
HK1132189A1 (en) 2010-02-19
SI2399579T1 (sl) 2013-07-31
US20170128374A1 (en) 2017-05-11
US20130251802A1 (en) 2013-09-26
PE20080765A1 (es) 2008-06-13
DK1897545T3 (da) 2010-02-08
US20130251800A1 (en) 2013-09-26
AR109797A2 (es) 2019-01-23
IL197214A (en) 2015-09-24
DK2292229T3 (da) 2012-08-13
RS52402B (sr) 2013-02-28
MA30766B1 (fr) 2009-10-01
JP2012167102A (ja) 2012-09-06
RS51678B (sr) 2011-10-31
MY146650A (en) 2012-09-14
ES2361721T3 (es) 2011-06-21
PL2292229T3 (pl) 2012-10-31
CN102688241A (zh) 2012-09-26
IL217794A (en) 2015-09-24
PT2399580E (pt) 2013-07-05
BRPI0714539B8 (pt) 2021-05-25
CL2014001029A1 (es) 2014-09-12
ES2388591T3 (es) 2012-10-16
US9775808B2 (en) 2017-10-03
DK2080514T3 (da) 2011-05-16
US20170128440A1 (en) 2017-05-11
PL2311459T3 (pl) 2012-12-31
KR101455914B1 (ko) 2014-11-03
US20130251797A1 (en) 2013-09-26
IL241121A (en) 2017-09-28
KR20120105566A (ko) 2012-09-25
CN101583360A (zh) 2009-11-18
CO6160317A2 (es) 2010-05-20
PL2399579T3 (pl) 2013-12-31
PL2384754T3 (pl) 2013-12-31
SI2070538T1 (sl) 2011-03-31
US20170319495A1 (en) 2017-11-09
PT2082742E (pt) 2011-03-02
JP5980881B2 (ja) 2016-08-31
EP2399579A1 (en) 2011-12-28
US20210169810A1 (en) 2021-06-10
US9492391B2 (en) 2016-11-15
DK2343071T3 (da) 2013-05-13
US8846086B2 (en) 2014-09-30
US20180153814A1 (en) 2018-06-07
US12246094B2 (en) 2025-03-11
RS51162B (sr) 2010-10-31
KR101787605B1 (ko) 2017-10-19
ES2358066T3 (es) 2011-05-05
US20150037413A1 (en) 2015-02-05
PT2292230E (pt) 2012-08-28
RS52779B (sr) 2013-10-31
US20190000767A1 (en) 2019-01-03
PL2080514T3 (pl) 2011-09-30
US20250073173A1 (en) 2025-03-06
JP5642736B2 (ja) 2014-12-17
TW200824722A (en) 2008-06-16
US20170128369A1 (en) 2017-05-11
MX360849B (es) 2018-11-20
ES2417335T3 (es) 2013-08-07
JP2012236835A (ja) 2012-12-06
US20150265600A1 (en) 2015-09-24
HRP20110147T1 (hr) 2011-04-30
DK2311459T3 (da) 2012-09-10
HRP20110375T1 (hr) 2011-06-30
AR103463A2 (es) 2017-05-10
ES2411696T3 (es) 2013-07-08
HK1154491A1 (en) 2012-04-27
EP2399580A1 (en) 2011-12-28
DE602007002596D1 (de) 2009-11-12
DE602007010974D1 (de) 2011-01-13
US20140030327A1 (en) 2014-01-30
SI2384754T1 (sl) 2013-07-31
EP2343071A1 (en) 2011-07-13
US20170348240A1 (en) 2017-12-07
EA200900343A1 (ru) 2009-08-28
EP2070538B1 (en) 2010-12-01
EP2292229A1 (en) 2011-03-09
ZA200900755B (en) 2009-12-30
IL217788A0 (en) 2012-03-29
NZ574447A (en) 2012-04-27
US20230310326A1 (en) 2023-10-05
PE20091184A1 (es) 2009-08-03
US20170128375A1 (en) 2017-05-11
PL1897545T3 (pl) 2010-02-26
CN107412179B (zh) 2020-09-04
PL2399580T3 (pl) 2013-12-31
AU2007287341A1 (en) 2008-02-28
EP2311459B1 (en) 2012-06-27
JP2016222698A (ja) 2016-12-28
US9084816B2 (en) 2015-07-21
US9775810B2 (en) 2017-10-03
KR101496510B1 (ko) 2015-03-03
US12280152B2 (en) 2025-04-22
EP2399579B1 (en) 2013-04-03
SI2080514T1 (sl) 2011-05-31
US20170319496A1 (en) 2017-11-09
KR20140049085A (ko) 2014-04-24
JP6286491B2 (ja) 2018-02-28
CN103861111A (zh) 2014-06-18
CN105213345A (zh) 2016-01-06
DE602007010963D1 (de) 2011-01-13
US20150335580A1 (en) 2015-11-26
CN105267170A (zh) 2016-01-27
DOP2009000026A (es) 2009-07-15
US20240408024A1 (en) 2024-12-12
US20250082581A1 (en) 2025-03-13
US10076498B2 (en) 2018-09-18
KR101649838B1 (ko) 2016-08-19
KR20120105565A (ko) 2012-09-25
HRP20120613T1 (hr) 2012-08-31
PE20191048A1 (es) 2019-08-06
PT2070538E (pt) 2011-03-02
CA2707204A1 (en) 2008-02-28
MX2009002023A (es) 2009-03-05
PT2080514E (pt) 2011-05-24
US9775811B2 (en) 2017-10-03
US20180369150A1 (en) 2018-12-27
US8821929B2 (en) 2014-09-02
US20150037412A1 (en) 2015-02-05
US9492392B2 (en) 2016-11-15
HK1165317A1 (en) 2012-10-05
IL197214A0 (en) 2009-12-24
PL2082742T3 (pl) 2011-05-31
US20210000747A1 (en) 2021-01-07
EP2292230A1 (en) 2011-03-09
JP2012229249A (ja) 2012-11-22
JP2012229250A (ja) 2012-11-22
PT2399579E (pt) 2013-06-24
HRP20090688T1 (hr) 2010-02-28
US11904055B2 (en) 2024-02-20
US11826472B2 (en) 2023-11-28
US8894987B2 (en) 2014-11-25
ME01482B (me) 2014-04-20
US20150335584A1 (en) 2015-11-26
BRPI0714539A2 (pt) 2014-02-25
EP2082742A1 (en) 2009-07-29
RS52793B (sr) 2013-10-31
US20150037411A1 (en) 2015-02-05
PL2070538T3 (pl) 2011-05-31
EP2311459A1 (en) 2011-04-20
IL217792A (en) 2015-09-24
US9486413B2 (en) 2016-11-08
US20130251801A1 (en) 2013-09-26
EP2070538A1 (en) 2009-06-17
US20250235407A1 (en) 2025-07-24
US20170319490A1 (en) 2017-11-09
US20180153815A1 (en) 2018-06-07
KR20170118249A (ko) 2017-10-24
US11964056B1 (en) 2024-04-23
US20140024669A1 (en) 2014-01-23
IL217787A0 (en) 2012-03-29
CY1113231T1 (el) 2016-04-13
ES2390419T3 (es) 2012-11-12
US8911719B2 (en) 2014-12-16
JP5373133B2 (ja) 2013-12-18
CY1111897T1 (el) 2015-11-04
CN105267170B (zh) 2019-01-01
US20130260015A1 (en) 2013-10-03
US20210000748A1 (en) 2021-01-07
ES2388615T3 (es) 2012-10-17
HK1165316A1 (en) 2012-10-05
SI1897545T1 (sl) 2010-01-29
MY153092A (en) 2014-12-31
US9770416B2 (en) 2017-09-26
CA2661573A1 (en) 2008-02-28
US9770417B2 (en) 2017-09-26
ME01064B (me) 2012-10-20
PT2384754E (pt) 2013-05-24
WO2008023261A1 (en) 2008-02-28
ME01580B (me) 2014-09-20
KR20110119847A (ko) 2011-11-02
ATE489954T1 (de) 2010-12-15
EA201171403A1 (ru) 2012-05-30
IL217791A (en) 2015-09-24
CY1113141T1 (el) 2016-04-13
US20210000749A1 (en) 2021-01-07
US20170246116A1 (en) 2017-08-31
HRP20130433T1 (en) 2013-06-30
DE602007012747D1 (de) 2011-04-07
JP2015044834A (ja) 2015-03-12
GT200900023BA (es) 2018-09-28
SI2399580T1 (sl) 2013-07-31
US8808741B2 (en) 2014-08-19
EP2343071B1 (en) 2013-03-20
IL217790A0 (en) 2012-03-29
DK2082742T3 (da) 2011-03-21
US9095614B2 (en) 2015-08-04
US10076499B2 (en) 2018-09-18
UA96306C2 (ru) 2011-10-25
US20170319491A1 (en) 2017-11-09
CR20140340A (es) 2014-10-16
EP2384754B1 (en) 2013-03-20
US20130251799A1 (en) 2013-09-26
US9492390B2 (en) 2016-11-15
KR101205579B1 (ko) 2012-11-28
ES2417334T3 (es) 2013-08-07
US8834925B2 (en) 2014-09-16
CY1110573T1 (el) 2015-04-29
US9101661B2 (en) 2015-08-11
RS51664B (sr) 2011-10-31
PL2292230T3 (pl) 2012-10-31
KR101514388B1 (ko) 2015-04-23
US9095615B2 (en) 2015-08-04
ME01339B (me) 2013-12-20
US20130251798A1 (en) 2013-09-26
DK2399580T3 (da) 2013-06-24
EA023807B1 (ru) 2016-07-29
SI2311459T1 (sl) 2012-10-30
US12396955B2 (en) 2025-08-26
KR20090045381A (ko) 2009-05-07
BR122016004010B1 (pt) 2020-11-24
PE20140854A1 (es) 2014-07-19
SI2343071T1 (sl) 2013-07-31
US20170319498A1 (en) 2017-11-09
US20240226019A1 (en) 2024-07-11
ATE444070T1 (de) 2009-10-15
HK1165318A1 (en) 2012-10-05
HK1133192A1 (en) 2010-03-19
HRP20120670T1 (hr) 2012-09-30
DK2399579T3 (da) 2013-06-17
MY161079A (en) 2017-04-14
NZ597760A (en) 2013-04-26
EA201300465A1 (ru) 2013-08-30
US20130259940A1 (en) 2013-10-03
RS51591B (sr) 2011-08-31
HK1154789A1 (en) 2012-05-04
EP2399580B1 (en) 2013-04-03
IN2015DN01813A (me) 2015-07-10
CN103861111B (zh) 2017-04-12
RS52463B (sr) 2013-02-28
DK2070538T3 (da) 2011-03-21
EP2292229B1 (en) 2012-05-23
CR10691A (es) 2009-06-05
US20170348241A1 (en) 2017-12-07
DK2384754T3 (da) 2013-05-06
US20170128370A1 (en) 2017-05-11
PL2343071T3 (pl) 2013-12-31
US20150335582A1 (en) 2015-11-26
US9775812B2 (en) 2017-10-03
CN107412179A (zh) 2017-12-01
ATE499101T1 (de) 2011-03-15
US20150265599A1 (en) 2015-09-24
CA2707204C (en) 2015-06-23
US8894988B2 (en) 2014-11-25
KR20150082669A (ko) 2015-07-15
DK2292230T3 (da) 2012-08-20
JO2858B1 (en) 2015-03-15
CL2007002485A1 (es) 2008-01-25
US9492393B2 (en) 2016-11-15
HK1154788A1 (en) 2012-05-04
TN2009000059A1 (fr) 2010-08-19
US20150335583A1 (en) 2015-11-26
EP2080514A1 (en) 2009-07-22
HRP20130444T1 (en) 2013-06-30
NZ608651A (en) 2014-07-25
EA031873B1 (ru) 2019-03-29
ES2411695T3 (es) 2013-07-08
CN101583360B (zh) 2014-02-26
US9763886B2 (en) 2017-09-19
EP2292230B1 (en) 2012-05-23
US20150028512A1 (en) 2015-01-29
JO3323B1 (ar) 2019-03-13
HRP20130539T1 (en) 2013-07-31
BRPI0714539B1 (pt) 2020-11-24
US20090081290A1 (en) 2009-03-26
IL241122B (en) 2019-05-30
PT1897545E (pt) 2009-12-16
CN102688241B (zh) 2017-04-12
US20170354607A1 (en) 2017-12-14
AR062511A1 (es) 2008-11-12
US20230270684A1 (en) 2023-08-31
SA07280459B1 (ar) 2011-07-20
US20170319488A1 (en) 2017-11-09
CN105213345B (zh) 2019-04-19
ME01550B (me) 2014-04-20
US9492389B2 (en) 2016-11-15
US11298322B2 (en) 2022-04-12
US8815289B2 (en) 2014-08-26
TWI341213B (en) 2011-05-01
UA104745C2 (ru) 2014-03-11
US20170319494A1 (en) 2017-11-09
IL217794A0 (en) 2012-03-29
AP2009004770A0 (en) 2009-02-28
BR122016004010B8 (pt) 2021-05-25
PE20150340A1 (es) 2015-02-28
ES2334466T3 (es) 2010-03-10
US20150335585A1 (en) 2015-11-26
IL241122A0 (en) 2015-11-30
JP2010501543A (ja) 2010-01-21
HRP20110130T1 (hr) 2011-03-31
ATE489953T1 (de) 2010-12-15
SI2082742T1 (sl) 2011-03-31
HRP20130434T1 (en) 2013-06-30
CN102743355B (zh) 2014-12-24
GT200900023A (es) 2010-11-05
US20170319492A1 (en) 2017-11-09
HK1138498A1 (en) 2010-08-27
DE202007011825U1 (de) 2008-04-30
CY1111896T1 (el) 2015-11-04
IL241121A0 (en) 2015-11-30
HK1246175A1 (zh) 2018-09-07
IL217792A0 (en) 2012-03-29
EP1897545A1 (en) 2008-03-12
US20170128373A1 (en) 2017-05-11
US20170128372A1 (en) 2017-05-11
EP2399579B9 (en) 2013-07-24
EP2384754A1 (en) 2011-11-09
CL2017000669A1 (es) 2017-11-10
KR20160099738A (ko) 2016-08-22
US20170319493A1 (en) 2017-11-09
US20130259938A1 (en) 2013-10-03
AR109796A2 (es) 2019-01-23
US11938225B2 (en) 2024-03-26
IL217791A0 (en) 2012-03-29
US20150265601A1 (en) 2015-09-24
CN102688213A (zh) 2012-09-26
AT11571U1 (de) 2011-01-15
US20230134700A1 (en) 2023-05-04
JP2012136543A (ja) 2012-07-19
US20130251796A1 (en) 2013-09-26
EP2082742B1 (en) 2010-12-01
US11304909B2 (en) 2022-04-19
HRP20120641T1 (hr) 2012-08-31
EP1897545B1 (en) 2009-09-30
US9486412B2 (en) 2016-11-08
DOP2011000255A (es) 2011-10-15
PT2311459E (pt) 2012-09-26
EA018311B1 (ru) 2013-07-30
US20140031381A1 (en) 2014-01-30
CA2661573C (en) 2010-10-26
US9545380B2 (en) 2017-01-17
IL217789A0 (en) 2012-03-29
RS52813B (sr) 2013-10-31
SI2292229T1 (en) 2012-09-28
ME01187B (me) 2011-10-31
US11304908B2 (en) 2022-04-19
US9775809B2 (en) 2017-10-03
HK1156845A1 (en) 2012-06-22
HK1118225A1 (en) 2009-02-06
US20170128371A1 (en) 2017-05-11
US20240115507A1 (en) 2024-04-11
SI2292230T1 (sl) 2012-09-28
US9763933B2 (en) 2017-09-19
US20170319497A1 (en) 2017-11-09
PT2343071E (pt) 2013-05-29
US20170319489A1 (en) 2017-11-09
RS52401B (sr) 2013-02-28
US20130259939A1 (en) 2013-10-03
CN102657630A (zh) 2012-09-12
EP2080514B1 (en) 2011-02-23
AU2007287341B2 (en) 2011-08-25
ES2357376T3 (es) 2011-04-25
KR101568100B1 (ko) 2015-11-12
CY1111887T1 (el) 2015-11-04
CY1113220T1 (el) 2016-04-13
CN102743355A (zh) 2012-10-24
PT2292229E (pt) 2012-08-28
US20170065527A1 (en) 2017-03-09
US20250352480A1 (en) 2025-11-20

Similar Documents

Publication Publication Date Title
ME01255B (me) Farmaceutski dozni oblici rezistentni na zloupotrebu koji sadrže opioidni analgetik
AU2002303718B2 (en) Abuse-resistant opioid dosage form
JP5728705B2 (ja) 薬物乱用抵抗性製剤
CN104080445B (zh) 能够对抗注射滥用的片剂
JP2006524249A5 (me)
RS52428B (sr) Dozni oblici otporni na menjanje
ME00398B (me) Oralne formulacije opijatnog agonista otporne na mehaničke, termičke i/ili hemijske promjene fizičkih osobina doznog oblika
CN101969930A (zh) 防滥用控制释放制剂
JP2018012711A (ja) 不正使用抵抗性の即時放出製剤
RS50817B (sr) Dozni oblik otporan na promene koji sadrži adsorbenti i sredstvo sa suprotnim dejstvom
AU2002303718A1 (en) Abuse-resistant opioid dosage form
JP2015500273A5 (me)
NZ571518A (en) Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion
RS62056B1 (sr) Farmaceutske kompozicije otporne na zloupotrebu
CA2812570A1 (en) Controlled release formulations of opioids
HK1198744A1 (en) Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
WO2015087241A1 (en) Crush-resistant solid oral dosage form
US10624856B2 (en) Non-extractable oral solid dosage forms
WO2019152002A1 (en) Non-extractable oral solid dosage forms
JP2021522319A (ja) 徐放性ピリドスチグミン組成物
HK1125296A (en) Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
HK1029749A1 (en) Opioid analgesics with controlled release